<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35413949</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Persistent COVID-19 symptoms in a community study of 606,434 people in England.</ArticleTitle><Pagination><StartPage>1957</StartPage><MedlinePgn>1957</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1957</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-29521-z</ELocationID><Abstract><AbstractText>Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3-5 of the REACT-2 study (n&#x2009;=&#x2009;508,707; September 2020 - February 2021), a representative community survey of adults in England, and replication data from round 6 (n&#x2009;=&#x2009;97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3-5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3-5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Whitaker</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1363-6537</Identifier><AffiliationInfo><Affiliation>School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Environment and Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Elliott</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadeau-Hyam</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8341-5436</Identifier><AffiliationInfo><Affiliation>School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Environment and Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riley</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Abdul Latif Jameel Institute for Disease &amp; Emergency Analytics, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darzi</LastName><ForeName>Ara</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7815-7989</Identifier><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Global Health Innovation at Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Graham</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6475-5056</Identifier><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Imperial Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Helen</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8238-5036</Identifier><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Imperial Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7511-5684</Identifier><AffiliationInfo><Affiliation>School of Public Health, Imperial College London, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Environment and Health, Imperial College London, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Imperial College Healthcare NHS Trust, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research Imperial Biomedical Research Centre, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research (HDR) UK London at Imperial College, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at Imperial College, London, UK. p.elliott@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L01341X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>22184</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200187/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_17114</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S019669/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/J008761/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>RE/18/4/34215</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>200861/Z/16/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V030841/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UNS32973</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19012</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>5</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35413949</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-29521-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urgent need for more research to understand Long Covid. https://royalsociety.org/news/2020/10/urgent-need-to-understand-long-covid/ (Accessed 31 March 2022).</Citation></Reference><Reference><Citation>Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Living with Covid19&#x2014;Second Review. https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/, 10.3310/themedreview_45225 (Accessed 31 March 2022).</Citation></Reference><Reference><Citation>Overview | COVID-19 rapid guideline: managing the long-term effects of COVID-19 | Guidance (NICE).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep.11. 10.1038/s41598-021-95565-8 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg. Health Eur. 2021;6:100122. doi: 10.1016/j.lanepe.2021.100122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (2021).</Citation></Reference><Reference><Citation>Cirulli, E. T. et al. Long-term COVID-19 symptoms in a large unselected population. Preprint at bioRxiv10.1101/2020.10.07.20208702 (2020).</Citation></Reference><Reference><Citation>Klein H, et al. Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin. Microbiol. Infect. 2021 doi: 10.1016/j.cmi.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.02.008</ArticleId><ArticleId IdType="pmc">PMC7884919</ArticleId><ArticleId IdType="pubmed">33607252</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong, S. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases53, 737&#x2013;754 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Living with Covid19. https://evidence.nihr.ac.uk/themedreview/living-with-covid19/, 10.3310/themedreview_41169 (Accessed 31 March 2022).</Citation></Reference><Reference><Citation>Arnold DT, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans, R. A. et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. 10.1016/S2213-2600(21)00383-0 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Venturelli S, et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol. Infect. 2021;149:e32. doi: 10.1017/S0950268821000145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268821000145</ArticleId><ArticleId IdType="pmc">PMC7873454</ArticleId><ArticleId IdType="pubmed">33461632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, et al. Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. J. Med. Virol. 2021;93:1175&#x2013;1179. doi: 10.1002/jmv.26459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26459</ArticleId><ArticleId IdType="pmc">PMC7461061</ArticleId><ArticleId IdType="pubmed">32841387</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-P&#xe9;rez O, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Y. et al. COVID symptoms, symptom clusters, and predictors for becoming a long-hauler: looking for clarity in the haze of the pandemic. Preprint at medRxiv10.1101/2021.03.03.21252086 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yomogida K, et al. Post-acute sequelae of SARS-CoV-2 infection among adults aged &#x2265;18 years&#x2014;Long Beach, California, April 1&#x2013;December 10, 2020. Morb. Mortal. Wkly. Rep. 2021;70:1274&#x2013;1277. doi: 10.15585/mmwr.mm7037a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7037a2</ArticleId><ArticleId IdType="pmc">PMC8445372</ArticleId><ArticleId IdType="pubmed">34529639</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg, B. et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 10.1038/s41591-021-01433-3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D., Pawelek, P. &amp; Gaughan, C. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK. Office for National Statistics. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021 (2021).</Citation></Reference><Reference><Citation>Ali A, Siddiqui AA, Arshad MS, Iqbal F, Arif TB. Effects of COVID-19 pandemic and lockdown on lifestyle and mental health of students: a retrospective study from Karachi, Pakistan. Ann. Med. Psychol. 2021 doi: 10.1016/j.amp.2021.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amp.2021.02.004</ArticleId><ArticleId IdType="pmc">PMC7883721</ArticleId><ArticleId IdType="pubmed">33612842</ArticleId></ArticleIdList></Reference><Reference><Citation>Morg&#xfc;l E, Kallitsoglou A, Essau CA. Psychological effects of the COVID-19 lockdown on children and families in the UK. Rev. Psicol. Cl&#xed;n. con Ni&#xf1;os Adolesc. 2020;7:42&#x2013;28.</Citation></Reference><Reference><Citation>Odriozola-Gonz&#xe1;lez P, Planchuelo-G&#xf3;mez &#xc1;, Irurtia MJ, de Luis-Garc&#xed;a R. Psychological effects of the COVID-19 outbreak and lockdown among students and workers of a Spanish university. Psychiatry Res. 2020;290:113108. doi: 10.1016/j.psychres.2020.113108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2020.113108</ArticleId><ArticleId IdType="pmc">PMC7236679</ArticleId><ArticleId IdType="pubmed">32450409</ArticleId></ArticleIdList></Reference><Reference><Citation>Timeline of UK government coronavirus lockdowns. https://www.instituteforgovernment.org.uk/charts/uk-government-coronavirus-lockdowns (accessed 31 March 2022).</Citation></Reference><Reference><Citation>Sykes DL, et al. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199:113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, et al. Characterising long COVID: a living systematic review. BMJ Glob. Health. 2021;6:e005427. doi: 10.1136/bmjgh-2021-005427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley S, et al. Resurgence of SARS-CoV-2: detection by community viral surveillance. Science. 2021;372:990&#x2013;995. doi: 10.1126/science.abf0874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf0874</ArticleId><ArticleId IdType="pmc">PMC8158959</ArticleId><ArticleId IdType="pubmed">33893241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward H, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat. Commun. 2021;12:905. doi: 10.1038/s41467-021-21237-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21237-w</ArticleId><ArticleId IdType="pmc">PMC7876103</ArticleId><ArticleId IdType="pubmed">33568663</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott J, et al. Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLoS Med. 2021;18:e1003777. doi: 10.1371/journal.pmed.1003777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003777</ArticleId><ArticleId IdType="pmc">PMC8478234</ArticleId><ArticleId IdType="pubmed">34582457</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: a multicenter study. J. Infect. 2021;83:237&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110627</ArticleId><ArticleId IdType="pubmed">33984399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward H, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: serial cross-sectional studies of 365,000 adults. Lancet Reg. Health Eur. 2021;4:100098. doi: 10.1016/j.lanepe.2021.100098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100098</ArticleId><ArticleId IdType="pmc">PMC8088780</ArticleId><ArticleId IdType="pubmed">33969335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, H. et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. 10.1101/2021.02.26.21252512 (2021).</Citation></Reference><Reference><Citation>Davies B, et al. Community factors and excess mortality in first wave of the COVID-19 pandemic in England. Nat. Commun. 2021;12:3755. doi: 10.1038/s41467-021-23935-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23935-x</ArticleId><ArticleId IdType="pmc">PMC8213785</ArticleId><ArticleId IdType="pubmed">34145260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward, H. et al. Global surveillance, research, and collaboration needed to improve understanding and management of long COVID. Lancet10.1016/S0140-6736(21)02444-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580495</ArticleId><ArticleId IdType="pubmed">34774190</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley S, et al. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: study protocol. Wellcome Open Res. 2020;5:200. doi: 10.12688/wellcomeopenres.16228.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16228.1</ArticleId><ArticleId IdType="pmc">PMC8095190</ArticleId><ArticleId IdType="pubmed">33997297</ArticleId></ArticleIdList></Reference><Reference><Citation>Imperial College London. Real-time Assessment of Community Transmission (REACT) study. https://www.imperial.ac.uk/medicine/research-and-impact/groups/react-study/ (accessed 31 March 2022).</Citation></Reference><Reference><Citation>Prokhorenkova, L., Gusev, G., Vorobev, A., Dorogush, A. V. &amp; Gulin, A. CatBoost: unbiased boosting with categorical features. Preprint at arXiv [cs.LG]: 1706.09516 (2017).</Citation></Reference><Reference><Citation>Hennig, C. fpc: Flexible Procedures for Clustering. 2020. https://cran.r-project.org/web/packages/fpc/index.html.</Citation></Reference><Reference><Citation>Hennig C. Cluster-wise assessment of cluster stability. Comput. Stat. Data Anal. 2007;52:258&#x2013;271. doi: 10.1016/j.csda.2006.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csda.2006.11.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Datta S. Comparisons and validation of statistical clustering techniques for microarray gene expression data. Bioinformatics. 2003;19:459&#x2013;466. doi: 10.1093/bioinformatics/btg025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btg025</ArticleId><ArticleId IdType="pubmed">12611800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen &amp; Julius, T. A Method of Establishing Groups of Equal Amplitude in Plant Sociology Based on Similarity of Species Content and Its Application to Analyses of the Vegetation on Danish Commons (I kommission hos E. Munksgaard, 1948).</Citation></Reference><Reference><Citation>Linzer DA, Lewis JB. poLCA: an R package for polytomous variable latent class analysis. J. Stat. Softw. 2011;42:1&#x2013;29. doi: 10.18637/jss.v042.i10.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v042.i10</ArticleId></ArticleIdList></Reference><Reference><Citation>EFS Survey. Version EFS Sprint 2020 (Questback GmbH, 2020).</Citation></Reference><Reference><Citation>Team RC. R Core Team R: A Language and Environment For Statistical Computing (R foundation for Statistical Computing, Austria, Vienna, 2018).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>